Pfizer cash flow statement
In fiscal 2025, Pfizer's operations generated $11.70bn of cash; it spent $2.63bn on capital projects, leaving free cash flow of $9.07bn. It returned $9.77bn in dividends.
Cash flow statement
| Fiscal year | 2007Dec 2007 | 2008Dec 2008 | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 13.4 | 18.2 | 16.6 | 11.5 | 20.2 | 16.7 | 17.7 | 16.2 | 16.8 | 15.8 | 12.6 | 14.4 | 32.6 | 29.3 | 8.7 | 12.7 | 11.7 | 14.2 |
| Depreciation and amortisation | 5.2 | 5.1 | 4.8 | 8.4 | 8.7 | 7.4 | 6.3 | 5.8 | 6.3 | 6.4 | 5.8 | 4.7 | 5.2 | 5.1 | 6.3 | 7.0 | 6.6 | 6.5 |
| Stock-based pay | 0.4 | 0.4 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.7 | 0.8 | 0.9 | 0.7 | 0.8 | 1.2 | 0.9 | 0.5 | 0.9 | 0.8 | 1.1 |
| Capital spending | 1.9 | 1.7 | 1.2 | 1.5 | 1.7 | 1.3 | 1.2 | 1.8 | 2.0 | 2.0 | 2.0 | 2.2 | 2.7 | 3.2 | 3.9 | 2.9 | 2.6 | 2.4 |
| Free cash flow | 11.5 | 16.5 | 15.4 | 9.9 | 18.6 | 15.4 | 16.5 | 14.4 | 14.8 | 13.8 | 10.5 | 12.2 | 29.9 | 26.0 | 4.8 | 9.8 | 9.1 | 11.8 |
| Free cash flow after stock pay | 11.0 | 16.2 | 15.0 | 9.5 | 18.2 | 14.9 | 16.0 | 13.7 | 14.0 | 12.9 | 9.9 | 11.4 | 28.7 | 25.2 | 4.3 | 9.0 | 8.3 | 10.7 |
| Dividends paid | 8.0 | 8.5 | 5.5 | 6.1 | 6.2 | 6.5 | 6.6 | 7.3 | 7.7 | 8.0 | 8.0 | 8.4 | 8.7 | 9.0 | 9.2 | 9.5 | 9.8 | 9.8 |
| Share buybacks | 10.0 | 0.5 | 0.0 | 1.0 | 9.0 | 8.2 | 16.3 | 5.0 | 5.0 | 12.2 | 8.9 | 0.0 | 0.0 | 2.0 | 0.0 | 0.0 | — | — |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6,721 | 2,335 | −582 | 4,603 | 5,348 | 2,615 | 835 | 5,375 |
| Depreciation and amortisation | 1,791 | 1,618 | 1,625 | 1,662 | 1,687 | 1,613 | 1,622 | 1,577 |
| Stock-based pay | 177 | 170 | 203 | 201 | 225 | 272 | 249 | 362 |
| Capital spending | 917 | 564 | 618 | 602 | 845 | 436 | 533 | 573 |
| Free cash flow | 5,804 | 1,771 | −1,200 | 4,001 | 4,503 | 2,179 | 302 | 4,802 |
| Free cash flow after stock pay | 5,627 | 1,601 | −1,403 | 3,800 | 4,278 | 1,907 | 53 | 4,440 |
Compare with peers
- Merck & Co. cash flow
- Astrazeneca PLC cash flow
- Bristol Myers Squibb cash flow
- Novo Nordisk A S cash flow
- Lilly (Eli) cash flow
Head to head: MRK vs PFEAZN vs PFEBMY vs PFELLY vs PFE
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies